Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia
Cancer · 01.03.2026 · 132 (5)
DOI: 10.1002/cncr.70275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 04.03.2026. Verfasst von Leah Lawrence. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA recently approved two menin inhibitors for the treatment of relapsed or refractory acute myeloid leukemia with NPM1 mutations: revumenib and ziftomenib. In addition, the FDA also approved the subcutaneous injection of anti‐CD38 monoclonal antibody daratumumab and hyaluronidase‐fihj for patients with high‐risk smoldering multiple myeloma, and oral TKI sevabertinib is approved for advanced HER2 ‐mutant NSCLC.
Zitieren
APA
Lawrence, L. (2026). Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia. Cancer, 132(5). https://doi.org/10.1002/cncr.70275
Vancouver
Lawrence L. Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia. Cancer. 2026;132(5). doi:10.1002/cncr.70275
BibTeX
@article{Lawrence2026,
author = {Lawrence, Leah},
title = {Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia},
journal = {Cancer},
year = {2026},
volume = {132},
number = {5},
doi = {10.1002/cncr.70275}
}
EUVIMED